AWH · Aspira Women'S Health Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $9.22M | $9.18M | $9.15M | $8.18M | $6.81M | $4.65M |
| Cost of Revenue | $3.30M | $3.70M | $3.89M | $3.87M | $3.75M | $3.42M |
| Gross Profit | $5.92M | $5.48M | $5.26M | $4.32M | $3.06M | $1.24M |
| R&D | $2.88M | $3.27M | $4.04M | $5.95M | $5.31M | $2.10M |
| SG&A | $7.96M | $10.35M | $12.27M | $16.18M | $13.26M | $8.27M |
| Total Operating Expenses | $13.83M | $21.76M | $24.11M | $37.08M | $35.66M | $19.22M |
| D&A | $37.0K | $92.0K | $199.0K | $264.0K | $302.0K | $265.0K |
| Operating Income | ($7.91M) | ($16.28M) | ($18.85M) | ($32.77M) | ($32.59M) | ($17.98M) |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | $0 |
| Net Income | ($12.78M) | ($13.09M) | ($16.69M) | ($27.17M) | ($31.66M) | ($17.91M) |
| EPS - Basic | ($0.37) | ($0.93) | ($1.81) | ($0.23) | ($0.28) | ($0.18) |
| EPS - Diluted | ($0.37) | ($0.93) | ($1.81) | ($0.23) | ($0.28) | ($0.18) |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.75M | $1.77M | $2.60M | $13.31M | $37.18M | $16.63M |
| Accounts Receivable | $1.21M | $990.0K | $1.46M | $1.25M | $1.03M | $865.0K |
| Inventory | $256.0K | $326.0K | $227.0K | $316.0K | $174.0K | $30.0K |
| Accounts Payable | $1.24M | $2.17M | $1.26M | $881.0K | $1.50M | $1.15M |
| Current Assets | $4.06M | $4.18M | $5.28M | $16.31M | $40.01M | $18.60M |
| Total Assets | $5.46M | $5.49M | $6.26M | $17.37M | $41.08M | $19.61M |
| Current Liabilities | $3.46M | $5.47M | $5.12M | $5.78M | $7.84M | $6.40M |
| Long-term Debt | $1.04M | $1.28M | $1.43M | $2.31M | $2.72M | $3.08M |
| Total Liabilities | $12.39M | $8.05M | $8.63M | $10.64M | $10.91M | $9.89M |
| Stockholders' Equity | ($6.93M) | ($2.56M) | ($2.37M) | $6.73M | $30.17M | $9.72M |
| Retained Earnings | ($544.18M) | ($531.40M) | ($518.30M) | ($498.90M) | ($471.73M) | ($440.07M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($7.03M) | ($12.11M) | ($15.89M) | ($32.19M) | ($27.39M) | ($14.73M) |
| Investing Cash Flow | ($401.0K) | ($37.0K) | ($24.0K) | ($232.0K) | ($184.0K) | ($490.0K) |
| Financing Cash Flow | $7.42M | $11.06M | $5.22M | $8.54M | $48.38M | $20.15M |
| CapEx | $16.0K | $37.0K | $24.0K | $232.0K | $184.0K | $490.0K |
| Free Cash Flow | ($7.04M) | ($12.15M) | ($15.92M) | ($32.42M) | ($27.58M) | ($15.22M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 64.2% | 59.7% | 57.5% | 52.8% | 45.0% | 26.6% |
| Operating margin | -85.9% | -177.3% | -205.9% | -400.4% | -478.5% | -386.6% |
| EBITDA margin | -85.5% | -176.3% | -203.8% | -397.1% | -474.1% | -380.9% |
| Net margin | -138.7% | -142.6% | -182.3% | -332.0% | -464.8% | -385.0% |
| Free cash flow margin | -76.4% | -132.3% | -173.9% | -396.1% | -404.9% | -327.3% |
| FCF / Net income | 0.55 | 0.93 | 0.95 | 1.19 | 0.87 | 0.85 |
| R&D / Revenue | 31.2% | 35.6% | 44.1% | 72.7% | 78.0% | 45.2% |
| SG&A / Revenue | 86.4% | 112.7% | 134.0% | 197.7% | 194.6% | 177.8% |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -234.2% | -238.5% | -266.5% | -156.4% | -77.1% | -91.3% |
| Return on equity | 184.4% | 510.9% | 705.7% | -403.7% | -104.9% | -184.2% |
| Return on invested capital | - | - | - | - | - | -111.0% |
| Liquidity | ||||||
| Current ratio | 1.17 | 0.76 | 1.03 | 2.82 | 5.10 | 2.91 |
| Quick ratio | 1.10 | 0.71 | 0.99 | 2.77 | 5.08 | 2.90 |
| Cash ratio | 0.51 | 0.32 | 0.51 | 2.30 | 4.74 | 2.60 |
| Leverage | ||||||
| Debt / Equity | -0.15 | -0.50 | -0.60 | 0.34 | 0.09 | 0.32 |
| Debt / Assets | 0.19 | 0.23 | 0.23 | 0.13 | 0.07 | 0.16 |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | -0.79 | -2.14 | -2.65 | 2.58 | 1.36 | 2.02 |
| Liabilities / Assets | 2.27 | 1.47 | 1.38 | 0.61 | 0.27 | 0.50 |
| Efficiency | ||||||
| Asset turnover | 1.69 | 1.67 | 1.46 | 0.47 | 0.17 | 0.24 |
| Inventory turnover | 12.89 | 11.36 | 17.15 | 12.23 | 21.55 | 113.83 |
| Days sales outstanding | 48d | 39d | 58d | 56d | 55d | 68d |
| Days inventory outstanding | 28d | 32d | 21d | 30d | 17d | 3d |
| Days payable outstanding | 137d | 214d | 118d | 83d | 146d | 123d |
| Cash conversion cycle | -61d | -143d | -39d | 2d | -74d | -52d |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | 0.4% | 0.3% | 11.9% | 20.1% | 46.5% | 2.5% |
| Revenue CAGR (3y) | 4.0% | 10.5% | 25.3% | 21.7% | 30.7% | 14.2% |
| Revenue CAGR (5y) | 14.7% | 15.1% | 24.6% | 21.3% | 20.9% | 16.4% |
| Gross profit growth (YoY) | 8.0% | 4.1% | 21.8% | 41.1% | 147.7% | 3.4% |
| Operating income growth (YoY) | 51.4% | 13.7% | 42.5% | -0.5% | -81.3% | -17.7% |
| Net income growth (YoY) | 2.4% | 21.5% | 38.6% | 14.2% | -76.8% | -17.5% |
| EPS growth (YoY) | 60.2% | 48.6% | -687.0% | 17.9% | -55.6% | 0.0% |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | 42.0% | 23.7% | 50.9% | -17.5% | -81.2% | -16.2% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -170.5% | -8.4% | - | -77.7% | 210.4% | 11.2% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$9.22M totalSingle Reportable Segment$9.22M · 100.0%
Product / service
$9.22M totalProduct$9.22M · 100.0%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
-87.46
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
6/9
Neutral
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- ✓Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- ✓Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: In Vitro & In Vivo Diagnostic Substances
Comparing Aspira Women's Health Inc. against the 5 most active filers in the same SIC group.